Treating cancer with a combination of a PD-1 antagonist and dinaciclib

Patent metadata

Field	Value
Publication number	US-9827309-B2
Application number	US-201414912771-A
Country	US
Kind code	B2
Filing date	Aug 15, 2014
Priority date	Aug 20, 2013
Publication date	Nov 28, 2017
Grant date	Nov 28, 2017

Abstract

The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and the CDK inhibitor dincaciclib, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L1.

First claim

The invention claimed is:

1. A method for treating a cancer in an individual comprising administering to the individual a combination therapy which comprises an isolated monoclonal antibody that binds to Programmed Death 1 protein (PD-1), wherein the isolated anti-PD-1 monoclonal antibody is MK-3475, and a dinaciclib compound, wherein the dinaciclib compound is the compound of Formula I

or a pharmaceutically acceptable salt of the compound of Formula I.

2. The method of claim 1 , wherein the cancer is a solid tumor.

3. The method of claim 1 , wherein the cancer is a Heme malignancy.

4. The method of claim 1 , wherein the individual has a cancer that tests positive for PD-L1 expression by an immunohistochemical (IHC) assay.

5. The method of claim 1 , wherein the cancer is bladder cancer, breast cancer, clear cell kidney cancer, head/neck squamous cell carcinoma, lung squamous cell carcinoma, malignant melanoma, non-small-cell lung cancer (NSCLC), ovarian cancer, pancreatic cancer, prostate cancer, renal cell cancer, small-cell lung cancer (SCLC), triple negative breast cancer, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin's lymphoma (HL), mantle cell lymphoma (MCL), multiple myeloma (MM), myeloid cell leukemia-1 protein (Mcl-1), myelodysplastic syndrome (MDS), non-Hodgkin's lymphoma (NHL), or small lymphocytic lymphoma (SLL).

Assignees

• Merck Sharp & Dohme

Inventors

• Strack Peter Richard
• Booher Robert
• Sriram Venkataraman
• Phillips Joseph H

Classifications

• A61P35/02

  specific for leukemia · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K39/395

  Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• C07K16/2818

  against CD28 or CD152 · CPC title